StockNews.AI
RVMD
StockNews.AI
140 days

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

1. RVMD will present at AACR with 11 abstracts, enhancing visibility. 2. First clinical data on zoldonrasib for lung cancer presented late-breaking. 3. RMC-5127, a promising new RAS inhibitor, will enter clinical development soon. 4. Pipeline expansion includes additional RAS(ON) inhibitors targeting various mutations. 5. Focus on RAS-driven therapies could increase investor interest in RVMD.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical presentations can drive investor sentiment. Previous similar events led to stock rises.

How important is it?

The AACR presentation could significantly impact RVMD's visibility and market perception.

Why Short Term?

Upcoming presentations at AACR may cause a prompt stock reaction. Immediate data release trends indicate quick market responses.

Related Companies

AMGNREGNMRNA
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title:Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitorPresenter:Anne Edwards, Ph.D.Abstract Number:ND06Session:New Drugs on the Horizon: Part 2Date/Time:April 27; 3:25 p.m. – 3:40 p.m. CST  Revolution Medicines Poster Presentations: Title:Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapyPresenter:Mariela Moreno Ayala, Ph.D.Abstract Number:6046Session:Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor ImmunityDate/Time:April 29; 2:00 p.m. – 5:00 p.m. CST   Collaborator Presentations Title:T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDACPresenter:Margo I. Orlen, Penn MedicineAbstract Number:6405Session:Checkpoints and Modulators of Tumor MicroenvironmentDate/Time:April 29; 3:25 p.m. – 3:40 p.m. CST   About Revolution Medicines, Inc.Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:media@revmed.cominvestors@revmed.com

Related News